Innate Pharma S.A. (IPHA) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Innate Pharma S.A. (IPHA) has outperformed PepGen (PEPG) over the past year, losing 22.1% versus a loss of 51.1%. Innate Pharma S.A. is the larger company by market cap ($169.8 million vs $166.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | PEPG |
|---|---|---|
| Share price | $1.52 | $2.40 |
| Market cap | $169.78M | $166.01M |
| 1-day change | -4.40% | +3.90% |
| YTD return | -13.14% | -63.13% |
| 1-year return | -22.05% | -51.12% |
| 5-year return | -74.11% | — |
| EPS (TTM) | $-0.59 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.71 | $7.80 |
| 52-week low | $1.17 | $1.31 |
| Distance from 52-week high | -43.91% | -69.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +338.82% | +324.58% |
| Average volume | 158.98K | 976.87K |
| Shares outstanding | 111.70M | 69.17M |
| Employees | 120 | 57 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPHA has outperformed PEPG by 29.1 percentage points over the past year.
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Healthcare · Biotechnology · 120 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Healthcare · Biotechnology · 57 employees
IPHA vs PEPG FAQ
Which is bigger, Innate Pharma S.A. or PepGen?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $169.78M compared with $166.01M for PepGen (PEPG).
Which stock has performed better over the past year, IPHA or PEPG?
IPHA returned -22.05% over the past 12 months, compared with -51.12% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and PepGen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.